Pfizer Inc, United States
Disclosure information not submitted.
1D-01 - Utilization of Near Real-Time, Pre-Adjudicated Claims Data for Timely Insights on the Risk of Guillain-Barré Syndrome (GBS) Following Respiratory Syncytial Virus (RSV) Vaccines during the Early Post-approval Period
Sunday, August 24, 202510:30 AM - 10:45 AM ET
